Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report
10.7774/cevr.2022.11.2.222
- Author:
Astrid HERZUM
1
;
Ilaria TRAVE
;
Federica D’AGOSTINO
;
Martina BURLANDO
;
Emanuele COZZANI
;
Aurora PARODI
Author Information
1. Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS, Genoa, Italy
- Publication Type:Case Report
- From:Clinical and Experimental Vaccine Research
2022;11(2):222-225
- CountryRepublic of Korea
- Language:English
-
Abstract:
We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivation. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been associated with an up-regulated T helper type 1-cell response, possibly favoring an immune system imbalance. Also, EBV reactivation has been postulated after COVID-19 vaccination, but only in the immunosuppressed. Noteworthy we report the first case of EBV viral reactivation associated with cutaneous manifestations in an immunocompetent patient after the COVID-19 vaccine.
